COVID-19-DM: The Effect of COVID-19 on Diabetes Mellitus

Sponsor
Uşak University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04592055
Collaborator
(none)
500
1
15.4
32.5

Study Details

Study Description

Brief Summary

The study aimed to evaluate the effect of SARS-COV-2 infection on metabolic status in patients with diabetes mellitus. Patients' HbA1c levels before and after SARS-COV-2 infection will be evaluated.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In this time pediods, all patients with RT-PCR positive for SARS-COV-2 will be analysed for the presence of diabetes mellitus. Previous HbA1c levels will be obtained from hospital records. In these patients, previous A1c levels and A1c levels 3 months after the SARS-COV-2 infection will be compared.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    The Effect of COVID-19 on the Glycemic Control in Patients With Diabetes Mellitus
    Actual Study Start Date :
    Mar 20, 2020
    Actual Primary Completion Date :
    Oct 15, 2020
    Anticipated Study Completion Date :
    Jul 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. A1c [6 months (3 months before and after COVID-19]

      the change in A1c levels

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • All hospitalised diabetic patients with RT-PCR- positive for SARS-COV-2 will be enrolled.
    Exclusion Criteria:
    • The absence of diabetes mellitus RT-PCR- negative for SARS-COV-2 Non-hospitalised patients

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Usak University Training and Research Hospital Usak Turkey 64200

    Sponsors and Collaborators

    • Uşak University

    Investigators

    • Principal Investigator: Cevdet Duran, Prof, Uşak University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Uşak University
    ClinicalTrials.gov Identifier:
    NCT04592055
    Other Study ID Numbers:
    • UU-DM002
    First Posted:
    Oct 19, 2020
    Last Update Posted:
    May 4, 2021
    Last Verified:
    May 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 4, 2021